PPL's positive view

PPL Therapeutics plc reported "positive" Phase IIc results for its transgenically produced alpha-1-antitrypsin (AAT) to treat cystic fibrosis. While skeptics might find that the results -- which were not significant -- were hardly positive, the company argues that the data may point it towards a more definitive, adequately powered trial design.

The 131-patient trial did not show an effect on the primary end point of time to first exacerbation, but a positive trend was seen in reduction in all